IGF-1 (Insulin-like Growth Factor 1)

Direct IGF-1 receptor agonist used clinically for pediatric primary IGF-1 deficiency (Increlex / mecasermin) and abused by bodybuilders as research-chem LR3 / DES variants for body comp and "localized" muscle growth. For Dylan at 20yo with peak endogenous IGF-1, this is supraphysiologic loading of a mitogenic, anti-apoptotic growth factor with documented severe hypoglycemia risk, theoretical cancer-promotion concern, and zero benefit case — unambiguous SKIP-AT-20 HIGH confidence. The "localized growth via IM injection" claim driving LR3 / DES popularity is largely myth; systemic effects dominate. Verdict reverses only for documented severe primary IGF-1 deficiency (clinically implausible at 20yo without growth-failure history).

What IGF-1 actually is

IGF-1 (insulin-like growth factor 1, somatomedin C) is a 70-amino-acid peptide hormone, structurally homologous to proinsulin (~50% sequence similarity), produced primarily in the liver in response to pituitary GH stimulation. It is the principal effector of GH's anabolic and mitogenic actions — most of what "GH does" is actually IGF-1 doing it on GH's behalf. Circulating IGF-1 is >99% bound to IGF binding proteins (IGFBPs, especially IGFBP-3 + acid-labile subunit), which sequester it and modulate tissue delivery. Free IGF-1 is the bioactive fraction.

Receptor + downstream signaling

IGF-1 binds the IGF-1 receptor (IGF-1R), a transmembrane receptor tyrosine kinase structurally similar to the insulin receptor (~60% homology in the kinase domain). At supraphysiologic levels, IGF-1 also weakly activates the insulin receptor itself — the molecular basis of hypoglycemia from IGF-1 dosing.

IGF-1R activation triggers two principal cascades:

1. PI3K → Akt → mTOR — drives protein synthesis, glucose uptake, anti-apoptotic survival signaling. This is the "anabolic / muscle growth" arm.
2. Ras → Raf → MEK → ERK (MAPK pathway) — drives cell proliferation, mitosis, growth. This is the "mitogenic" arm — and the basis of cancer-promotion concerns at supraphysiologic levels.

The variants

• Native rhIGF-1 (mecasermin / Increlex): Recombinant DNA-derived human IGF-1, identical sequence. Subject to full IGFBP sequestration. Half-life ~5.8 hours. The only FDA-approved form.
• IGF-1 LR3 (Long-R3 IGF-I): 83 amino acids — adds a 13-residue N-terminal extension and substitutes Arg for Glu at position 3. Reduces IGFBP binding affinity by ~100-fold (some sources cite 1000-fold), evading sequestration → dramatically more "free" / bioactive IGF-1 in circulation. Half-life ~20-30 hours (vs. ~6 hr native). Originally developed as a cell-culture growth supplement, never intended for human use. In vivo potency vs. native IGF-1: most credible estimates are 2-3× molar potency, with one in vitro study showing ~10× via IGFBP evasion. The "100×" figure in popular bodybuilding literature is the IGFBP affinity reduction, not the in vivo functional potency — these are commonly conflated.
• IGF-1 DES (Des(1-3) IGF-I): Native IGF-1 with the first three N-terminal amino acids removed. Reduces IGFBP affinity by ~10-fold and increases IGF-1R binding affinity ~10×. Very short half-life (~20-30 minutes). Marketed for "localized hyperplasia" via IM injection at target muscles.

Why bodybuilders use LR3 / DES specifically

Native rhIGF-1 is short-acting, IGFBP-sequestered, and expensive (Increlex). LR3's IGFBP evasion + long half-life means a single subcutaneous injection produces sustained supraphysiologic free IGF-1. DES's short half-life + IGFBP evasion means it is positioned by injection-site marketing as "stays where you put it" — a claim mostly belied by pharmacokinetic reality (peptides distribute systemically once injected; "localization" is an injection-site-only phenomenon over very brief windows).

Hypoglycemia mechanism

IGF-1 has ~1-10% the metabolic potency of insulin at the insulin receptor, but supraphysiologic IGF-1 levels (especially via LR3's IGFBP-evading kinetics) produce sufficient insulin-receptor crossover to cause acute, sometimes severe, hypoglycemia — particularly when injected fasted, in conjunction with insulin/exogenous insulin, in conjunction with intense exercise (which independently increases muscle glucose uptake), or after carbohydrate restriction. Mecasermin's FDA label requires dosing within 20 minutes of a meal/snack precisely for this reason.